0000000000591842

AUTHOR

Chiara Simeoli

0000-0003-4275-337x

showing 5 related works from this author

The degree of urinary hypercortisolism is not correlated with the severity of cushing’s syndrome

2017

Cushing syndrome (CS) is characterized by increased morbidity and mortality compared to the general population. However, there are patients who have more clinical aggressive forms than others. Aim of the study is to evaluate whether the degree of hypercortisolism, defined by the number of times urinary free cortisol (UFC) levels exceed the upper limit of the normal range (ULN), is related to the worsening of phenotypic features, as well as metabolic and cardiovascular parameters, in a cohort of CS patients. A cross-sectional study was conducted on 192 patients with active CS, consecutively presenting at the outpatients' clinic of the University Hospitals of Ancona, Naples, and Palermo. Pati…

AdultMalemedicine.medical_specialtyPediatricsHydrocortisoneEndocrinology Diabetes and MetabolismUrinary systemCushing hypercortisolismPopulationCushing syndrome severity030209 endocrinology & metabolismGastroenterologySeverity of Illness IndexDexamethasoneUrinary free cortisolSettore MED/13 - Endocrinologia03 medical and health sciencesCushing syndromeYoung Adult0302 clinical medicineEndocrinologyDiabetes mellitusInternal medicineUrinary free cortisolmedicineHumanseducationCushing SyndromeCushing syndrome comorbiditieeducation.field_of_studyS syndromebusiness.industryDegree of hypercortisolismMiddle Agedmedicine.diseaseCross-Sectional Studies030220 oncology & carcinogenesisDexamethasone suppression testCohortFemalebusiness
researchProduct

Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion.

2020

Context: Glucocorticoid (GC) replacement therapy in patients with adrenal insufficiency (AI) is life saving. After over 50 years of conventional GC treatment, novel formulations are now entering routine clinical practice. Methods: Given the spectrum of medications currently available and new insights into the understanding of AI, the authors reviewed relevant medical literature with emphasis on original studies, prospective observational data and randomized controlled trials performed in the past 35 years. The Expert Opinion of a panel of selected endocrinologists was sought to answer specific clinical questions. The objective was to provide an evidence-supported guide, for the use of GC in…

medicine.medical_specialtyHydrocortisoneHormone Replacement TherapyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismlaw.inventionSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyGlucocorticoidRandomized controlled triallawPrednisonemedicineAdrenal insufficiencyOutpatient clinicHumansDosingIntensive care medicineGlucocorticoidsbusiness.industryAddison; Adrenal insufficiency; Cortisone acetate; Glucocorticoid; Hydrocortisone; Prednisonemedicine.diseaseItalyTransgender hormone therapyCortisone acetate030220 oncology & carcinogenesisPrednisoneObservational studybusinessMedical literaturemedicine.drugAddisonAdrenal InsufficiencyJournal of endocrinological investigation
researchProduct

Effect of Cabergoline on Metabolism in Prolactinomas.

2013

<b><i>Introduction:</i></b> Hyperprolactinemia has been implicated in the pathogenesis of obesity and glucose intolerance and is reportedly associated with an impaired metabolic profile. The current study aimed at investigating the effects of 12- and 60-month treatment with cabergoline (CAB) on metabolic syndrome (MetS) in patients with prolactinomas. <b><i>Patients and Methods:</i></b> 61 patients with prolactinomas (13 men, 48 women, 41 with microadenoma, 20 with macroadenoma), aged 34.4 ± 10.3 years, entered the study. In all patients, prolactin (PRL) and metabolic parameters were assessed at diagnosis and after 12 and 60 months of continuo…

AdultMalemedicine.medical_specialtyTime FactorsEndocrinology Diabetes and MetabolismTreatment outcomeprolactinomasAntineoplastic AgentsSettore MED/13 - EndocrinologiaPathogenesisCellular and Molecular NeuroscienceEndocrinologyInsulin resistanceMetabolic DiseasesCabergolineInternal medicinePrevalenceMedicineHumansInsulinPituitary NeoplasmsProspective StudiesErgolinesAdiposityMetabolic SyndromeDose-Response Relationship DrugEndocrine and Autonomic Systemsbusiness.industryPituitary tumorsMetabolismFastingmedicine.diseasePrognosisProlactinProlactinHyperprolactinemiaEndocrinologyTreatment OutcomeprolactinomacabergolineFemaleMetabolic syndromeInsulin Resistancebusinessmetabolismmedicine.drug
researchProduct

Is diabetes in Cushing's syndrome only a consequence of hypercortisolism?

2014

ObjectiveDiabetes mellitus (DM) is one of the most frequent complications of Cushing's syndrome (CS). The aim of this study was to define the changes in insulin sensitivity and/or secretion in relation to glucose tolerance categories in newly diagnosed CS patients.DesignCross-sectional study on 140 patients with CS.MethodsA total of 113 women (80 with pituitary disease and 33 with adrenal disease, aged 41.7±15.7 years) and 27 men (19 with pituitary disease and eight with adrenal disease, aged 38.1±20.01 years) at diagnosis were divided according to glucose tolerance into normal glucose tolerance (CS/NGT), impaired fasting glucose and/or impaired glucose tolerance (CS/prediabetes), and diabe…

AdultMalemedicine.medical_specialtyHydrocortisoneEndocrinology Diabetes and Metabolismmedicine.medical_treatmentCushing's syndromeSettore MED/13 - EndocrinologiaPrediabetic StateImpaired glucose toleranceEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusInsulin SecretionGlucose IntoleranceDiabetes MellitusmedicineHumansInsulinPrediabetesCushing SyndromeRetrospective StudiesCushing DiabetesGlucose tolerance testhypercortisolismmedicine.diagnostic_testbusiness.industryInsulinGeneral MedicineGlucose Tolerance TestMiddle Agedmedicine.diseaseImpaired fasting glucoseDiabetes and MetabolismCross-Sectional StudiesPhenotypeEndocrinologyDiabetes Mellitus Type 2diabeteFemaleInsulin ResistanceMetabolic syndromebusinessAdult; Cross-Sectional Studies; Cushing Syndrome; Diabetes Mellitus Type 2; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Hydrocortisone; Insulin; Insulin Resistance; Male; Middle Aged; Phenotype; Prediabetic State; Retrospective Studies; Endocrinology Diabetes and Metabolism; EndocrinologyType 2European Journal of Endocrinology
researchProduct

COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficien…

2020

In November 2019, the Italian Society of Endocrinology (SIE) has published a consensus statement on the tailoring of glucocorticoid replacement in adrenal insufciency [1]. A few months later, a novel severe acute respiratory syndrome coronavirus (SARS-CoV2) has been recognized as responsible for COVID-19. The outbreak has now reached pandemic level, with a high global mortality rate [2]. From February on, Italy has experienced an exponential rise in the infected which is estimated to reach 200,000 people, with an overall lethality of approximately 10% [3]. A recent Chinese series of nearly 50,000 patients with confrmed COVID-19 infection found that approximately one-out-of-fve (19%) evolve …

medicine.medical_specialty2019-20 coronavirus outbreakConsensusCoronavirus disease 2019 (COVID-19)Hormone Replacement TherapyEndocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralConsensuEndocrinologyGlucocorticoidmedicineAdrenal insufficiencyHumansSteroids.Hormone replacement therapyViralIntensive care medicinePandemicsAdrenal insufficiency; COVID-19; Glucocorticoids; SARS-CoV2GlucocorticoidsPandemicbusiness.industryCoronavirus InfectionCOVID-19Pneumoniamedicine.diseaseCOVID-19 Drug TreatmentItalyExpert opinionSARS-CoV2SteroidsbusinessCoronavirus InfectionsCoronavirus InfectionsAdrenal insufficiencyHuman
researchProduct